Theis Terwey
Co-founder of GH Research; former Chief Executive Officer
Data updated
Research Footprint
Theis Terwey appears in 5 tracked papers (2021–2026), most studied alongside 5-MeO-DMT and Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Healthy Volunteers.
Most-cited paper: A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression (81 citations).
Frequent co-authors: Johannes Ramaekers, Nathalie Mason and Jan Reckweg.
Background & Research
Theis Terwey is a biotechnology executive and co-founder of GH Research in Dublin, Ireland, where he has been involved in the development of inhaled mebufotenin (5-MeO-DMT, GH001) for psychiatric indications. He is listed as an author on multiple GH001 clinical-trial papers, including studies in treatment-resistant depression, postpartum depression, healthy volunteers, and work on the peak experience scale. Public filings and company materials identify him as part of GH Research’s leadership and product-development team.
Key Impact
He is a co-founder and longtime leader of GH Research, the company developing GH001 and related psychedelic medicines.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →